Go Deep
AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Sep 2026 | 18,334 | 92.8 | 17.99 | 0.13 | 6,280.00 |
| Sep 2026 | 18,330 | 96.2 | 17.99 | 0.13 | 6,280.00 |
| Sep 2026 | 18,330 | 96.2 | 17.99 | 0.13 | 6,280.00 |
| Oct 2026 | 18,159 | 89.3 | 17.27 | 0.13 | 6,031.00 |
| Oct 2026 | 17,401 | 86.0 | 16.72 | 0.13 | 5,837.00 |
AstraZeneca Pharma India Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 6,827,900,000.0 | 5,786,100,000.0 | 6,115,700,000.0 | 5,590,900,000.0 |
| Net Profit | 379,300,000.0 | 448,800,000.0 | 325,900,000.0 | 542,200,000.0 |
| EPS | 15.2 | 17.9 | 13.0 | 21.7 |
AstraZeneca Pharma India Limited Revenue & Profit: Last 4 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Revenue | 22,725,800,000.0 | 17,132,900,000.0 | 12,955,300,000.0 | 10,029,700,000.0 |
| Net Profit | 1,875,200,000.0 | 1,157,400,000.0 | 1,615,100,000.0 | 992,900,000.0 |
| EPS | 75.0 | 46.3 | 64.6 | 39.7 |
AstraZeneca Pharma India Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 19,891,000,000.0 | 15,181,200,000.0 | 10,780,300,000.0 | 9,848,700,000.0 | — |
| Total Liabilities | 11,163,100,000.0 | 7,477,700,000.0 | 3,661,100,000.0 | 3,961,800,000.0 | — |
| Total Equity | 8,727,900,000.0 | 7,703,500,000.0 | 7,119,200,000.0 | 5,886,900,000.0 | — |
Owes vs Owns
AstraZeneca Pharma India Limited owed ₹0.56 for every ₹1 it owned in Mar 2026, up from ₹0.40 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.56× | 0.49× | 0.34× | 0.40× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
AstraZeneca Pharma India Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 22.5%Receivables 10.7%Inventory 51.6%Fixed assets (tangible) 5.9%Other assets 9.0%
How it's funded — Mar 2026
Short-term debt 0.7%Long-term debt 4.9%Payables 39.3%Other liabilities 11.2%Shareholders' equity 43.9%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 447.7 | 536.1 | 505.6 | 500.3 |
| Receivables | 213.7 | 184.9 | 153.1 | 107.5 |
| Inventory | 1,027.3 | 548.5 | 227.9 | 190.2 |
| Fixed assets (tangible) | 117.5 | 63.6 | 64.8 | 70.2 |
| Intangible assets | 0.0 | 0.7 | 2.1 | 0.0 |
| Long-term investments | 4.0 | 3.6 | 0.0 | 3.1 |
| Other assets | 178.9 | 180.7 | 124.5 | 113.5 |
| Liabilities & equity | ||||
| Short-term debt | 13.9 | 6.3 | 1.8 | 3.5 |
| Long-term debt | 96.8 | 29.4 | 2.8 | 3.7 |
| Payables | 782.7 | 456.3 | 196.5 | 227.9 |
| Other liabilities | 222.9 | 255.7 | 165.0 | 161.1 |
| Shareholders' equity | 872.8 | 770.4 | 711.9 | 588.7 |
| Net tangible assets | 872.8 | 769.7 | 709.8 | 588.7 |
AstraZeneca Pharma India Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | -151,400,000.0 | 653,600,000.0 | 278,700,000.0 | 582,900,000.0 | — |
| Investing Activities | 186,900,000.0 | 308,000,000.0 | 217,400,000.0 | 181,100,000.0 | — |
| Financing Activities | -919,700,000.0 | -655,900,000.0 | -443,800,000.0 | -244,800,000.0 | — |